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   As reported in the previous short communication1), the authors have 
been engaged in isolating a protein anabolic factor from hog pancreas for 
the last eighteen years. The extraction procedure of fraction B reported 
herein, which is more effective against 15 myasthenic patients than any 
other drugs, has been established for the last five years.
   Until the discovery of the calcitonin2)3), it had been generally 
accepted that calcium and bone metabolisms were regulated exclusively 
by parathormone. However, since T. OGATA' S report in 19244) 
numerous studies5) on the parotid gland have been achieved in Japan, 
of which extract, named Parotin, was found to cause hypocalcemia6), 
promote protein anabolism7) and be effective on the patients of bone 
diseases and myasthenia gravis8). In 1947 K. MURATA and N. TAKIZAWA9) 
described that the hypertrophy of both the pancreatic islets and parotid 
glands were histologically found in autopsy among Japanese under-
nourished people, despite of the atrophy of hypophysis, thyroid and 
adrenal glands. In 1954 TAKAOKA proposedlO) an existency of a compen-
satory or feedback mechanism between the parotid gland and pancreas 
in diabetes mellitus. 
   Based on these phenomena, the authors have been engagad for the 
last eighteen years in isolating a new protein anabolic hormone from 
ho-g Pancreas. Manv kinds of pancreatic preparations have been
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extracted, and their effects have been tested with bioassay in rabbits. 
This paper describes isolation and its property of a hypocalcemic factor 
from pancreas and its clinical effect on the patients of myasthenia 
gravis. 
              MATERIALS AND METHODS 
   A hypocalcemic factor was extracted from aceton dried powder of 
porcine pancreas with a distilled water at 0--'5°C for sixty minutes and 
then was precipitated at pH 4.0 by the addition of 2N HCl. This 
precipitate was dissolved in a distilled water, its solution was adjusted 
to pH 5.4, and resulting precipitate was discarded. The supernatant 
was adjusted again to pH 4.0 and its precipitate was dissolved again 
in a distilled water of pH 7.0. Solid ammonium sulfate was gradually 
added to the solution with stirring to give 0.4 saturation. The 
precipitate was collected by centrifugation and dissolved in a water. 
After dialysis this fraction designated fraction A was lyophilized. The 
clear supernatant fluid was brought to 0.8 saturation with ammonium 
sulfate. The precipitate was dissolved in approximately 100 ml of 
distilled water. This solution designated fraction B was dialyzed 
against distilled water and lyophilized. From 100g of aceton dried 
powder, 250 mg. of the fraction B are obtainable, which exhibits 
usually 20-80 units of proteinase activity. 
   In vivo stuides, mixed bred male rabbits weighing about 2.5 kg 
were used. They were fed with rabbit chow pellets ad libitum in the 
laboratory for at least four weeks before the experiment, and fasted 
for about 18 hours just before bioassay. 
   Fraction B was injected intravenously into four healthy male 
rabbits. Blood samples were collected from the marginal ear vein prior 
to and 1.5, 3.0 and 6.0 hours after the injections. The bioassay data 
obtained by pancreatic extracts were always compared with those of 
the control group injected physiological saline. 
   Serum calcium, total amino acid and urea nitrogen in the blood 
specimens were determined by the method described in the preliminary 
report'). Serum inorganic phosphate was determined by the method of 
FISKE and S(JBBAROW11) and blood glucose by HAGEDORN-JENSEN 'S method'2) . 
                        RESULTS 
   As shown in Table 1, 2 and 3, serum calcium level reduced by 
the administration of fraction B approximately 12% and inorganic 
phoshate about 24%. However, hematocrit value was not markedly 
changed and blood sugar level was neither changed entirely. Decreases 
of the total protein, amino acid-N, urea-N and potassium in serum 
of rabbits were observed as reported previously') .
Table 1 Hypocalcemic effect
                    Time Prior 3° 6° 
   Material to injection after injection 
     Pancreatic extract 
       (No. 5046-B) 12. 3mg/ d I 11.3mg/ dl 10.9mg/ dl 
     Saline 12.8 12.0 12.2 
             Each group consisted of 4 rabbits
Table 2 Inorganic phosphate
        _ Time Prior 30 60 
   Material to injection after injection 
     Pancreatic extract 3 .54mg/dl 2.80mg/dl 2.69mg/dl         (No . 5046-B) 
I 
     Saline 2.92 2.93 2.92 
i
Table 3 Hematocrit
                     Time Prior 1 .5° 3.0° 6.00 9.0° 12° 
   Material to injection after injection 
     Pancreatic extract 44 .7% 42.0 43.5 40.1 44.3 43.0         (No. 5046-B) 
i 
     Saline 43.0 35.6 41.0 40.5 41.5 38.5
   The number of circulating leukocyte decreased markedly within 1.5 
and 3.0 hours after intravenous injection due to neutropenia and then 
increased significantly until 9.0 or 12.0 hours, as shown in the pre-
liminary report." 
   Fraction B was used clinically for the patients of myasthenia gravis 
of severe generalized type, who were admitted to our Department of 
Medicine for the last five years. On admission, they had been all 
routinely treated with usual anti-cholinesterase drugs and others, as 
previouely reportedl). When their clinical conditions became stationary, 
they were given additionally with daily 3-9 mg. of fraction B 
intramuscularly. When their clinical signs and symptoms improved 
markedly, the anti-cholinesterase drugs were reduced gradually and in 
case 1,2 and 11 finally suspended. 
   Table 4 demonstrates the clinical significances of fraction B on 
this disease, which were divided into 4 groups. The symbol -F +, 
represents the most significant effect on the patients, who are now
Table 4 Effects of pancreatic extract on myasthenia gravis
                                                   Duration of Dosage of Duration 
      Age Sex Symptoms on Admission Symptoms Extract of Effect                                                    before 
                                  _ Treatment (mg/day) Treatment 
                  Weakness of four extremities. 
  1 26 9 Diplopia. Blephaloptosis. 6y 9 4y.                  fficulty in s eech & swallowing . 
                  Lagophthalmos 
  2 25 Difficulty in walking.                                                      5 2y.6m. }}                   plopia . Blephaloptosis. 
  3 46 ' 9 Weakness of four extremities. ' 1 iI 9 3y.4m. + 
  4 17 9 Weakness of four extremities. 3 6 2y. ff                  Diplopia . Blephaloptosis. 
                  Weakness of four extremities. 
  5 35 9 Blephaloptosis. Difficulty in 1 I' 3 2 ~i -H-
                  speech. 
  6 28 Y Weakness of four extremities. -)Y. 4M. 3 2                  Difficulty in swallowing . 
                  Weakness of four extremities.7 51 
Diplopia. Blephaloptosis. 2y 6 2 ii + 
                  Weakness of four extremities. 
  8 55 6 Blepha.loptosis. Difficulty in 2 /1 6 2 i~ + 
                  swallowing. 
  9 28 Weakness of four extremities. Diplopia 12 // 3 7.5m. =_ 
. 
  10 32 Weakness of four extremities. 7y.5m. 3^-6 7 y +                 Diplopia
. 
                                                             -- --- 
11 29 Weakness of four extremities. 71. 6 10 // Difficulty in swallowing
. 
                  Weakness of four extremities. 12 30 I 9 Diplopia. Blephaloptosis. ly.6m. 3 4 /i 
                 Difficulty in swallowing. 
i 
               ~, Weakness of four extremities. 3m . 3 3  13 22 Diplopia . Blephaloptosis. ly. ~~ + 
                  Weakness of four extremities. 
 14 50 9 Blephaloptosis. 2y. 3 1 ~~ + 
                 Difficulty in speech & swallowing. 
                  Weakness of four extremities
 15 14 9 Diplopia. Blephaloptosis. ly.6m. 3 5 ~~ }{-
                 Difficulty in speech. 
                                    y: year m: month
enjoying an usual active life as healthy people without any drug, in-
cluding fraction B. They are probably healed. The symbols, -H-, + and 
± represent respectively marked effects, fair effects on general clinical 
status and improvement of some clinical symptoms with the continuous 
administration of the fraction B and minimized amounts of anti-
cholinesterase drugs. These data suggest that fraction B is more 
effective than any other drugs on the disease. Case 1 had been bed-
ridden for 4 years in our hospital and thereafter was treated with 
pancreatic extract for 2 years. Her clinical conditions improved
completely. Case 2 has the same clinical course and got married. 
Photographs 1 and 2 show the clinical effect on case 6 before and after 
the treatment with fraction B. She was markedly improved and gained 
body weight, as observed in many pati 2nts. Table 5 demonstrates the 
effect of this extract on myasthenic state of case 11 in paralell with the 
increasing doses from 3 mg. to 6 and 9 mg. EMG of the same patient 
showed the increase of the initial response from 4.5mV (July 16, 1968) 
to 9.2mV (July 19, 1969) as shown in Fig. 1 and 2. 
            Photo. 1 Phto. 2
Photo 1 and 2 show the facial symptoms of case 6 before and after treatment 
with pancreatic extract. She gained body weight about 10 kg.
   Because the fraction B is of protein quality containing a little 
amount of protease, it should be administered intramuscularly with 
increasing dose. The first injection should be given 0.5 mg. of the 
extract intramuscularly. When no fever occurs, the dose would be 
increased gradually up to 3 mg. by increasing of 0.5 mg. at a time 
with an interval of 2 or 3 days. We have never experienced such 
severe side-effects as allergy or exanthem, but seldom observed 
localized redness, which diminished spontaneously within a day. 
However, we have been careful to take the past history concerning 
allergy.
Table 5 Clinical course of No . 11
F. S. 29 aged female 
Myasthenia gravis
                 Fig. 1 JUL 16, 1968 
Relationship between frequency of nerve stimulation and pattern of 
evoked muscle action potentials
                   Fig. 2 JUL. 19, 1969 
Relationship between frequency of nerve stimulation and pattern of 
evoked muscle action potentials
                    DISCUSSION 
   While our investigation started before the proposal of calcitonin, 
such idea as our pancreatic preparations has never been described 
up-to-date. 
   During the former half period of this long term research project, 
the contamination of insulin in the extract made us frequently 
impossible to continue bioassay with rabbits due to hypoglycemia. 
Furthermore, the effect of our preparations in the bioassay with rabbits 
and their protease activity as impurity varied markedly until 1963, 
when the extraction procedure described in the text was established. 
Fraction B is believed to be more effective to myasthenic patients than 
any other drugs, including anti-cholinesterase drugs, spironolactone 
and Parotin. Further purification, however, is now in progress in 
order to isolate a preparation without any protease activity. It failed to 
demonstrate the direct evidence of the pancreatic extract as hormone. 
The mechanism of the effect of this pancreatic extract to myasthenic 
patients is still obscure.
                    SUMMARY 
   The pancreatic extract was partially purified from aceton dried 
powder of hog pancreas. It caused hypocalcemia and is more effective 
to myasthenic patients of severe generalized type than any other 
drugs. However, its mechanism of the effect to myasthenic patients 
remains still obscuse. 
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